Login / Signup

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.

Danny RischinBrett G M HughesNicole Basset-SéguinDirk SchadendorfSamantha BowyerSabiha Trabelsi MessaiFriedegund MeierThomas Kurt EigentlerVictoria Casado EcharrenBrian SteinMarie Beylot-BarrySophie DalacBrigitte DrénoMichael R MigdenAxel HauschildChrysalyne D SchmultsAnnette M LimSuk-Young YooAnne J PaccalyApostolos PapachristosJenny-Hoa NguyenEmmanuel OkoyeFrank SeebachJocelyn BoothIsrael LowyMatthew G FuryAlexander D Guminski
Published in: Journal for immunotherapy of cancer (2024)
Extended dosing of cemiplimab 600 mg intravenously Q4W exhibited substantial antitumor activity, rapid and durable responses, and an acceptable safety profile in patients with advanced CSCC. These results confirm that cemiplimab is a highly active therapy for advanced CSCC. Additional data would help ascertain the benefit-risk profile for the 600 mg intravenous dosing regimen compared with the approved regimen.
Keyphrases
  • squamous cell carcinoma
  • electronic health record
  • big data
  • lymph node metastasis
  • low dose
  • radiation therapy
  • machine learning
  • rectal cancer
  • data analysis
  • deep learning